Symyx Board Again Rejects Certara Bid | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Symyx Technologies said last night after the close of the market that its board of directors has once again rejected Certara's bid to acquire the firm for $5.75 per share, or around $200 million, saying that it does not constitute a superior offer to Accelrys' bid to acquire the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.